Search

Your search keyword '"Lung non small cell cancer"' showing total 2 results
Start Over Descriptor "Lung non small cell cancer" Journal lung cancer
2 results on '"Lung non small cell cancer"'

1. Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop

Author

Susana Benlloch, Carlos Camps, Rafael Sirera, Carlota Costa, Miguel Angel Molina-Vila, Jose L uis Ramirez-Serrano, Ana Giménez-Capitán, Christian Rolfo, Rafael Rosell, Eloisa Jantus-Lewintre, Miguel Taron, Sara Simonetti, Imane Chaib, Pedro Mendez, and Isabel Bover

Subjects
Serum, Cancer Research, Unclassified drug, Blood sampling, Molecular biology, Colorectal cancer, Disabled homolog 2 interacting protein, Disease, Gene mutation, Metastasis, Plasma, Breast cancer, Carcinoma, Non-Small-Cell Lung, Medicine, Priority journal, Cell DNA, Prostate cancer, Messenger RNA, MicroRNA, B Raf kinase, Gene expression profiling, Peripheral blood prognostic markers, Lung non small cell cancer, Oncology, Tumor Markers, Biological, Reverse transcription polymerase chain reaction, Biomarker (medicine), Lung cancer, BRCA1 protein, Liver cancer, Human, Pulmonary and Respiratory Medicine, EGFR, Cancer invasion, DNA repair, DNA determination, DAB2IP, Blood analysis, Epidermal growth factor receptor 2, Health care organization, Genetic screening, Humans, Workshop, Epidermal growth factor receptor, business.industry, Protein, Circulating tumor cell, Circulating tumor cells, MICROBIOLOGIA, DNA, BRCA1, Nonhuman, Note, medicine.disease, K ras protein, RNA, Protein expression, Gene expression, business, Non-small-cell lung cancer, Biomarkers, Phosphatidylinositol 3 kinase
Abstract

The majority of non-small-cell lung cancer (NSCLC) patients present with locally advanced (35%) or metastatic disease (40%); in this setting, it is of the utmost importance to balance efficacy with toxicity. However, with platinum combinations, survival has reached a " plateau" , with median overall survival times of a mere 10-12 months, making it mandatory to search for new strategies and to identify more effective treatment. Molecular characteristics can be more informative than clinical features in predicting clinical benefit, and the identification of molecular markers can help define subgroups of patients who are likely to respond to different treatments, thus avoiding unnecessary toxicities and costs and providing the maximum benefit to each patient. Here we review research on biomarker assessment that was presented during the Molecular Biology Workshop held in Palma de Mallorca on 25 November 2010, during the Fifth Educational Symposium of the Spanish Lung Cancer Group. © 2011.

Published
2011
Full Text
View/download PDF

2. Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases

Author

Voulgaris, E., Pentheroudakis, George, Pappa, L., Bafa, M., Goussia, Anna, Dalezis, P., Tsombanidou, C., Geromichalos, G., Papageorgiou, A., Koutsilieris, M., Malamou-Mitsi, Vassiliki D., Pavlidis, Nicholas, Pavlidis, Nicholas [0000-0002-2195-9961], and Pentheroudakis, George [0000-0002-6632-2462]

Subjects
Male, Oncology, Lung Neoplasms, Mouse, medicine.medical_treatment, Receptors, CXCR4/metabolism, Cancer cell, Treatment response, Mice, Cxcr4, Breast cancer, 80 and over, Disease course, Aged, 80 and over, Chemokine receptor cxcr4, Correlation analysis, Tumor localization, Secondary lymphoid tissue chemokine, Urologic neoplasms, Inbred c57bl, Lung cancer, Immunocytochemistry, Human, Pulmonary and Respiratory Medicine, Receptors, CXCR4, medicine.medical_specialty, Urinary system, Inbred balb c, Major clinical study, Article, Lung Neoplasms/metabolism/mortality/pathology/*urine, Primary tumor, Kidney function, Humans, Validation process, Lung small cell cancer, Animal model, Small cell lung carcinoma, Animal experiment, Aged, Adrenal metastasis, Non-small-cell lung, Urine sediment, medicine.disease, Mice, Inbred C57BL, Human cell, Urine cytology, Case-Control Studies, Carcinoma, Non-Small-Cell Lung/metabolism/mortality/pathology/*urine, Protein expression, Chemokine CCL21/metabolism, Neoplasm Transplantation, Cancer Research, Urologic Neoplasms/secondary, Mammary neoplasms, Cancer staging, Animal tissue, Carcinoma, Lewis Lung, Lung neoplasms, Carcinoma, Non-Small-Cell Lung, Lewis lung, Cytology, Receptors, Carcinoma, Lewis Lung/pathology/urine, Tumor volume, Overall survival, Middle aged, Priority journal, Mice, Inbred BALB C, Heterologous, Cytokeratin, medicine.diagnostic_test, Middle Aged, medicine.anatomical_structure, Lung non small cell cancer, Chemokine, Female, Animal cell, Adult, Urologic Neoplasms, Transplantation, Heterologous, Histopathology, Case-control studies, Neoplasm transplantation, Urinary tract tumor, Pathophysiology, Urothelial metastases, Experimental, Internal medicine, medicine, Animals, Human tissue, Mammary Neoplasms, Experimental/pathology/urine, Neoplasm Staging, Platinum, Transplantation, Chemotherapy, Lung, Chemokine CCL21, Performance status, business.industry, Carcinoma, Mammary Neoplasms, Experimental, Nonhuman, Small Cell Lung Carcinoma, Chemokine ccl21, Neoplasm staging, Small Cell Lung Carcinoma/metabolism/mortality/pathology/*urine, business, Controlled study, Occult
Abstract

Purpose: To study the phenomenon of positive urine cytology in patients with lung cancer in the absence of obvious urothelial metastases. Patients and methods: 150 patients with small (SCLC) and non-small cell lung cancer (NSCLC) of all stages and 3 control groups were prospectively studied. Immunocytochemical study (cytokeratins 7-20, TTF1) in all positive urine specimens and chemokine profile (CXCR4, CCL21) study of the primary tumor in selected positive patients was performed. In experimental study, C57Bl/6 BALB/C mice injected with LLC lung and 4T1 mammary cancer cells were used for the detection of positive urine cytology. Results: 11% of patients with NSCLC, 7% of patients with SCLC and none of the control group had positive urine cytology. In NSCLC, metastatic disease and high tumor burden positively correlated (p = 0.01 and 0.03 respectively) with the phenomenon. In SCLC, correlation with extensive disease and multiple metastatic sites (p = 0.02 and 0.04 respectively) was found. No correlation was found in either group with: age, gender, histology, performance status, line of chemotherapy, previous platinum-based chemotherapy, adrenal metastases, renal function, abnormal urinary sediment, response to chemotherapy and overall survival (p = 0.9). Distinctive chemokine expression was identified in positive patients studied and was not observed in negative patients (×2 p = 0.008). In the experimental study, only the LLC lung cancer cells were detected in the urine cytology of mice. Conclusion: This phenomenon, carrying undefined pathophysiological mechanisms, seems to characterize only patients with metastatic/extensive disease and high tumor burden. Further studies are needed to validate our preliminary chemokine expression results. © 2010 Elsevier Ireland Ltd. 73 1 51 58

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results